Khaled W Halwani
Hospital ResidentCards
About
Research
Publications
2026
Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis
Njei B, Al-Ajlouni YA, Tanih DN, Kanmounye US, Boateng S, Halwani KW, Nguefang GL, Lim J. Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis. Cost Effectiveness And Resource Allocation 2026 DOI: 10.1186/s12962-026-00741-0.Peer-Reviewed Original Research